OBJECTIVES
Lupus nephritis (LN) often progresses despite therapy, and current complete renal response (CRR) definitions tolerate residual proteinuria deemed suboptimal in other glomerulopathies. Belimumab, the first biologic approved for active LN, may enable deeper remission, but its real-world effectiveness is unknow...
Marc Xipell, M. C. Garbarino, I. Rodríguez-Pintó et al.· Rheumatology· 0 citations
For many years, systemic lupus erythematosus (SLE) pathogenesis was interpreted primarily through the lens of adaptive immunity, with emphasis on disruption of T- and B-cell tolerance, autoantibody production, immune-complex deposition, and complement activation. However, a major shift in the understanding of SLE immun...
Marina Selva-Del Río, Pablo Balado-Simó, X. Bosch-Amate et al.· Archives of Rheumatology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.